NEVPF (Abliva AB) Other Current Liabilities : $0.63 Mil (As of Sep. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Abliva AB Other Current Liabilities?

Abliva AB's other current liabilities for the quarter that ended in Sep. 2024 was $0.63 Mil.

Abliva AB's quarterly other current liabilities increased from Mar. 2024 ($0.48 Mil) to Jun. 2024 ($0.61 Mil) and increased from Jun. 2024 ($0.61 Mil) to Sep. 2024 ($0.63 Mil).

Abliva AB's annual other current liabilities increased from Dec. 2021 ($0.86 Mil) to Dec. 2022 ($1.36 Mil) but then declined from Dec. 2022 ($1.36 Mil) to Dec. 2023 ($0.68 Mil).

Abliva AB Other Current Liabilities Historical Data

The historical data trend for Abliva AB's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abliva AB Other Current Liabilities Chart

Abliva AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Current Liabilities

Get a 7-Day Free Trial

Abliva AB Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Other Current Liabilities	Get a 7-Day Free Trial															-	-	-	-	-

Abliva AB Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

Abliva AB Other Current Liabilities Related Terms

Thank you for viewing the detailed overview of Abliva AB's Other Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Abliva AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abliva AB (OTCPK:NEVPF) » Definitions » Other Current Liabilities

Comparable Companies

Traded in Other Exchanges

ABLI:Sweden 0QDU:UK NTP:Germany

Address

Scheeletorget 1, Medicon Village, Lund, SWE, 223 81

Website

https://www.abliva.com

Abliva AB is a Swedish company that is active in pharmaceutical development. It develops medicines for the treatment of primary mitochondrial diseases. These congenital, rare, and often very severe diseases occur when the cell's energy provider, the mitochondria, does not function properly. The portfolio includes projects at different stages and ranges from the early discovery phase to the clinical phase. . The company is focused on two projects. KL1333, a powerful NAD+ and NADH regulator, in late-stage development and has been granted orphan drug designation in Europe and the US. NV354, an energy replacement therapy, has just completed preclinical development.